At a glance
- MOTS-C activates AMPK, the same longevity pathway exercise triggers
- SS-31 (elamipretide) protects cardiolipin and restores mitochondrial ATP output
- FOXO4-DRI selectively triggers apoptosis in senescent cells
- Most longevity peptides have animal data, not human lifespan evidence
- Epithalon and bioregulators are dosed in short repeated courses
Longevity is the most overhyped category in the peptide space. The honest framing up front: most of these compounds have a compelling mechanism and animal data, not human lifespan evidence. Three of them are worth understanding anyway, because the mechanism is specific enough to be a real research target rather than a vibe.
MOTS-C: the exercise-mimetic
MOTS-C is a peptide encoded inside your mitochondria. It activates AMPK, the master energy sensor that exercise and caloric restriction also switch on. In mice, MOTS-C prevented diet-induced weight gain and insulin resistance and improved metabolic flexibility (Lee et al., Cell Metabolism 2015). It is the closest thing in this category to a molecular echo of a workout, which is why it shows up in both the fat-loss and longevity conversations. Protocols are on the MOTS-C dosage chart.
SS-31 (elamipretide): repairing the powerhouse
Mitochondria decline with age, and SS-31 targets the specific failure point. It binds cardiolipin, a lipid unique to the inner mitochondrial membrane, and protects the structure of the cristae so the electron transport chain keeps making ATP (Szeto, 2014). Unlike most compounds here, SS-31 (under the name elamipretide) has been through human clinical trials for primary mitochondrial disease. The SS-31 dosage chart has the research protocol and the SS-31 research page covers the mechanism in depth.
FOXO4-DRI: clearing senescent cells
Senescent cells are cells that have stopped dividing but refuse to die, and they leak inflammatory signals that age the tissue around them. FOXO4-DRI is a senolytic: it disrupts the FOXO4 to p53 interaction that keeps senescent cells alive, tipping them into apoptosis while sparing healthy cells (Zhang et al., 2025). It is the most mechanistically interesting entry here and the least proven in humans. Dosing is on the FOXO4-DRI dosage chart.
Epithalon and NAD+: the bioregulator and the coenzyme
Epithalon is a synthetic tetrapeptide studied by Khavinson and colleagues for telomerase activation and melatonin normalization in research models. It is dosed in short repeated courses, not continuously, which is standard for the bioregulator class. NAD+ is not a peptide at all but a coenzyme central to energy metabolism and sirtuin activity, and it belongs in any longevity stack conversation. See the Epithalon dosage chart, the NAD+ dosage chart, and the Pinealon dosage chart for the neuro-focused bioregulator.
The realistic stack
| Peptide | Target | Human evidence |
|---|---|---|
| MOTS-C | AMPK / metabolic | Preclinical |
| SS-31 | Mitochondrial membrane | Clinical trials (mito disease) |
| FOXO4-DRI | Senescent cells | Preclinical |
| Epithalon | Telomerase / circadian | Limited, single lineage |
| NAD+ | Energy coenzyme | Mechanistic |
Bottom line: SS-31 has the strongest human trail because elamipretide is a real clinical program. MOTS-C and FOXO4-DRI are the most interesting mechanisms with the thinnest human data. Treat every protocol here as a research reference, not a lifespan guarantee.
Purity matters more here, not less
Longevity peptides are run for months, so a mislabeled or underfilled vial is a long, expensive mistake. Check the certificate of analysis first on our peptide lab test database. These compounds are available as research vials from Ascension Peptides with 50% off using code ENHANCED.
This article is for research and educational purposes only. It is not medical advice, and none of these compounds is proven to extend human lifespan. Consult a qualified healthcare professional before making any health decision.
